Brief: X4 Pharmaceuticals Announces Proposed Underwritten Public Offering
23/10/2025 23:36
X4 Pharmaceuticals Inc XFOR.O: X4 PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN PUBLIC OFFERING X4 PHARMACEUTICALS INC - PROCEEDS TO FUND PHASE 3 DEVELOPMENT OF MAVORIXAFOR Source text: ID:nGNX5xXd5F Further company coverage: XFOR.O
Recent news on X4 Pharmaceuticals
See all newsBrief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: X4 Pharmaceuticals Q2 Operating Expenses USD 25.197 Million
X4 Pharmaceuticals Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule